Opportunity ID: 332518

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-AR-21-015
Funding Opportunity Title: Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Disease Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases, and Sjgrens Syndrome (UC2 Clinical Trial Optional)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.121 — Oral Diseases and Disorders Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Mar 31, 2021
Last Updated Date: Mar 31, 2021
Original Closing Date for Applications: Jul 15, 2021
Current Closing Date for Applications: Jul 15, 2021
Archive Date: Aug 20, 2021
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Special district governments
Private institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Public and State controlled institutions of higher education
Small businesses
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Independent school districts
Native American tribal organizations (other than Federally recognized tribal governments)
Others (see text field entitled “Additional Information on Eligibility” for clarification)
City or township governments
County governments
State governments
Native American tribal governments (Federally recognized)
For profit organizations other than small businesses
Public housing authorities/Indian housing authorities
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name: National Institutes of Health
Description: Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Disease Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases, and Sjgrens Syndrome (UC2 Clinical Trial Optional)
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-AR-21-015.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
Email: FBOWebmaster@OD.NIH.GOV
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-F Use for due dates on or after May 25, 2020 PKG00266292 Jun 15, 2021 Jul 15, 2021 View

Package 1

Mandatory forms

332518 RR_SF424_2_0-2.0.pdf

332518 PHS398_CoverPageSupplement_5_0-5.0.pdf

332518 RR_OtherProjectInfo_1_4-1.4.pdf

332518 PerformanceSite_2_0-2.0.pdf

332518 RR_KeyPersonExpanded_2_0-2.0.pdf

332518 RR_Budget_1_4-1.4.pdf

332518 PHS398_ResearchPlan_4_0-4.0.pdf

332518 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf

Optional forms

332518 RR_SubawardBudget30_1_4-1.4.pdf

332518 PHS_AssignmentRequestForm_3_0-3.0.pdf

2025-07-09T21:09:55-05:00

Share This Post, Choose Your Platform!

About the Author: